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 Abstract:  X-linked adrenoleukodystrophy (X-ALD) is a 
severe inherited neurodegenerative disorder character-
ized by adrenal insufficiency and graded damage in 
the nervous system. Loss of function of the peroxisomal 
ABCD1 fatty-acid transporter, resulting in the accumula-
tion of very long-chain fatty acids in organs and plasma, 
is the genetic cause. Treatment with a combination of 
antioxidants halts the axonal degeneration and locomo-
tor impairment displayed by the animal model of X-ALD, 
and is a proof of concept that oxidative stress contributes 
to axonal damage. New evidence demonstrates that meta-
bolic failure and the opening of the mitochondrial per-
meability transition pore orchestrated by cyclophilin D 
underlies oxidative stress-induced axonal degeneration. 
Thus, cyclophilin D could serve as a therapeutic target for 
the treatment of X-ALD and cyclophilin D-dependent neu-
rodegenerative and non-neurodegenerative diseases. 
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 Introduction: general features of 
X-linked adrenoleukodystrophy and 
animal models of the disease 
 X-linked adrenoleukodystrophy (X-ALD: McKusick no. 
300100) is a rare neurometabolic disease character-
ized by progressive demyelination within the central 
nervous system (CNS), axonopathy in the spinal cord, and 
adrenal insufficiency. This inheritable disorder is caused 
by mutations in the ABCD1 (ALD) gene located in Xq28. 
This encodes for the peroxisomal ABCD (ALD protein) 
 transporter (Mosser et al. , 1993 ), which is involved in 
importing very long-chain fatty acids (VLCFAs) and 
very long-chain fatty acid – Coenzyme A (VLCFA – CoA) 
esters into the peroxisome, where they are degraded by 
 β -oxidation (Singh et al. , 1984 ; Wanders et al. , 1987 ; van 
Roermund et al. , 2008 ; Fourcade et al. , 2009 ). Defective 
function of the ABCD1 transporter leads to VLCFA accu-
mulation in most organs and plasma, and elevated levels 
of VLCFAs are used as a biomarker for the biochemical 
diagnosis of the disease (Berger and Gartner , 2006 ; Moser 
et al. , 2007 ). X-ALD is the most common monogenic leu-
kodystrophy and peroxisomal disorder, occurring in at 
least 1 out of 16 800 people (Bezman et al. , 2001 ). 
 Four major disease variants have been described:
 –  Adrenomyeloneuropathy (AMN), a late-onset form 
presenting a slow progression and characterized by a 
peripheral neuropathy and distal axonopathy in the 
spinal cord. This phenotype is often, but not always, 
associated with axonal or demyelinating peripheral 
neuropathy and can affect both adult men and 
women. 
Brought to you by | UNAM
Authenticated | 132.248.107.131
Download Date | 4/3/13 1:29 AM
622      J. L ó pez-Erauskin et al.: Antioxidants as a treatment for mitochondrial dysfunction
 –  AMN with cerebral demyelination or cAMN. This 
form mainly affects adult males and can turn into an 
inflammatory phenotype in many cases. 
 –  The cerebral inflammatory demyelination form that 
affects boys, adolescents and adult males or cALD. 
 –  An adrenal insufficiency (Addison ’ s disease) that 
affects boys, adolescents and adult males, and 
presents a partial penetrance. 
 Patients suffering this last variant of X-ALD have a high 
risk of developing later cerebral demyelination or AMN 
(Laureti et al. , 1996 ; Engelen et al. , 2012 ). The cerebral 
inflammatory demyelinating forms of X-ALD are fatal if 
not treated by bone marrow transplant in the early stages 
of the disease (Shapiro et al. , 2000 ; Peters et al. , 2004 ). 
 Irrespective of its location or variant, a cardinal event 
of X-ALD is axonal damage. In variants affecting the brain, 
demyelination appears to be the main cause of severe 
axonal damage and neuronal death, whereas in AMN 
axonal damage in the spinal cord and peripheral nerves is 
the predominant feature, with demyelination as a second-
ary process (Powers et al. , 2000 ; Ferrer et al. , 2010 ). 
 It is well known that a murine model offers great 
advantages over postmortem patient materials, such as 
the possibility of carrying out a longitudinal characteri-
zation of the disease process, thus allowing the discrimi-
nation of causative events from epiphenomena. Three 
mouse models for X-ALD were independently generated 
following a classical strategy of knocking out the  Abcd1 
gene, which is located in the X chromosome of the mouse 
genome (Forss -Petter et al., 1997 ; Kobayashi et al. , 1997 ; 
Lu et al. , 1997 ). All three mouse models showed high 
levels of VLFCAs in the nervous tissue, adrenal glands 
and other organs as a representative signature, but in 
contrast, none of them displayed cerebral demyelina-
tion or inflammatory signs up to 6 months of age (Forss -
Petter et al., 1997 ; Kobayashi et al. , 1997 ; Lu et al. , 1997 ). 
However, an analysis of animals at 16 months of age with 
a pure C57BL/6J genetic background showed histological 
signs of axonopathy in the sciatic nerves, and interest-
ingly, at 20 – 22 months of age mice displayed microglia 
activation, astrocytosis, and axonal swelling and damage 
(Pujol et al. , 2002, 2004 ). All these effects were con-
comitant with locomotor alterations and delays of motor 
nerve conduction velocities (Pujol et al. , 2002; Ferrer 
et al. ,  2005). Thus, this mouse model resembles the char-
acteristic axonopathy in the spinal cord of patients with 
pure AMN (Pujol et al. , 2002 ), and it constitutes a good 
model for dissecting physiopathogenetic mechanisms. A 
second peroxisomal transporter and the closest homolog, 
the ABCD2 protein, shares functions in the import of 
C26:0, the main VLCFA accumulated in X-ALD (Pujol 
et al. , 2004 ; Ferrer et al. , 2005 ; Fourcade et al. , 2009 ). The 
double knockout  Abcd1/Abcd2 displays a more severe 
and earlier onset axonopathy that facilitates preclinical 
testing (Pujol et al. , 2004 ). 
 Although considerable efforts have been made in 
the development of efficient therapies against this fatal 
disease, pharmacological treatment options for X-ALD 
are scarce (reviewed in Berger et al. , 2010 ). We and others 
have demonstrated that oxidative stress is a common 
feature in X-ALD patients (Vargas et al. , 2004 ; Powers et 
al. , 2005 ; Fourcade et al. , 2010 ) as well as in the animal 
model, appearing very early on in the latter (Fourcade 
et al. , 2008 ). These results have prompted us to explore 
antioxidant treatment as a therapeutic option, and to this 
end we recently performed preclinical trials with a cock-
tail of antioxidants containing  α -tocopherol, N-acetyl-
cysteine and  α -lipoic acid in  Abcd1  -  mice. The results were:
 –  correction of oxidative damage to proteins and DNA; 
 –  correction of metabolic deficits including levels of 
ATP, NADH and pyruvate kinase activity; 
 –  reversal of axonal damage; and 
 –  reversal of the locomotor disability provoked by the 
accumulation of VLCFA in the  Abcd1/Abcd2 null 
mutants (Galino et al. , 2011 ; Lopez -Erauskin et al., 
2011 ). 
 A Phase II clinical trial with these antioxidants is cur-
rently in progress (NCT01495260). However, the molecular 
mechanisms mediating the beneficial effect of the antioxi-
dants remain unclear. 
 The purpose of this review is to highlight recent evi-
dence about the molecular events occurring during the 
cellular damage triggered by oxidative stress and the role 
played by cyclophilin D (CypD). Moreover, using data 
obtained with antioxidant treatment we will discuss the 
potential of using CypD as a mechanistic action model of 
how antioxidants are able to prevent axonal neurodegen-
eration. CypD comes to center stage as an essential step 
in mitochondrial collapse in neurodegenerative diseases 
including X-ALD. 
 Very long-chain fatty acids and 
oxidative stress 
 Although patients with X-ALD, characterized by abnormal 
VLCFA accumulation, were first described at the beginning 
of the last century, the demonstration that VLCFA accumu-
lation led to toxicity was only recently made. In 2008, our 
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group and others reported that VLCFA accumulation was 
not an epiphenomenon but, rather, that VLCFA in excess 
was toxic (Fourcade et al. , 2008 ; Hein et al. , 2008 ). Using 
human fibroblasts we showed that VLCFA accumulation 
generates important levels of radical oxygen species (ROS), 
decreases reduced glutathione (GSH) levels, and induces 
inner mitochondrial membrane depolarization (Fourcade 
et al. , 2008 ). In agreement with these data, parallel studies 
performed in rat primary neural cell cultures showed that 
VLCFAs are able to dissipate inner mitochondrial mem-
brane potential and increase intracellular calcium levels 
in oligodendrocytes (Hein et al. , 2008 ). Similarly, the 
treatment of VLCFAs increases ROS levels in the murine 
oligodendrocyte cell line 158N (Baarine et al. , 2012a , b ) and 
human neuronal cell line SK-NB-E (Zarrouk et al. , 2012 ), 
besides inducing a decrease in GSH levels and the dis-
sipation of the inner mitochondrial membrane potential 
(Baarine et al. , 2012a ,b; Zarrouk et al. , 2012 ). Moreover, 
incubation of fibroblasts with C26:0 only provoked oxi-
dative damage to proteins and lipids in X-ALD fibroblasts 
and not in control fibroblasts (Fourcade et al. , 2008 ). In 
addition, the X-ALD fibroblasts present increased vulner-
ability to oxidative stress under depleted GSH conditions 
(Fourcade et al. , 2008 ). 
 Oxidative damage is indeed the main etiopathogenic 
factor in X-ALD disease; it is observed very early on in the 
spinal cord of the mouse model and in fibroblasts from 
patients with X-ALD (Fourcade et al. , 2008 ; Singh and 
Pujol , 2010 ; Lopez -Erauskin et al., 2011 ). This damage is 
characterized by an increase in the quantitative markers 
of protein lipoxidation (malondialdehyde-lysine), glycoxi-
dation and lipoxidation (carboxyethyl-lysine), together 
with markers of the direct carbonylation of proteins (glu-
tamic semialdehyde and aminoadipic semialdehyde) in 
the pre-symptomatic stages of the X-ALD mouse model 
(Fourcade et al. , 2008 ). In accordance with these data, 
signs of oxidative modifications have also been described 
in postmortem X-ALD brains, as well as in plasma and 
blood cells (Vargas et al. , 2004 ; Powers et al. , 2005 ; 
Fourcade et al. , 2010 ). 
 These  in vivo observations support the surrogate use 
of skin-derived fibroblasts from patients as a successful 
in vitro model for the study of the molecular mechanisms 
of this disease instead of human CNS tissues, which are 
only accessible postmortem. 
 It is not clear how VLCFAs trigger oxidative stress, but 
it is worth noting that VLCFAs (C  ≥ 22:0) are usually con-
stituents of complex lipids, such as gangliosides, phos-
phatidylcholine, and cholesterol ester fractions of brain 
myelin and of proteolipid protein. While the gangliosides 
of normal individuals lack VLCFAs (Garashi et al. , 1976 ), 
the gangliosides in the brain of X-ALD patients contain 
28 – 50% VLCFAs. Their incorporation in lipid membranes 
may cause cell and organelle dysfunction (Powers and 
Moser , 1998 ). In fact, lysophosphatidylcholine fractions 
have been found to be particularly enriched with C26:0 
(Hubbard et al. , 2006 ). Moreover, an excess of lisophos-
phatidylcholine-C24:0 species produces inflammatory 
demyelination when injected in normal mice (Eichler 
et al. , 2008 ). 
 Oxidative stress and metabolic 
failure are intertwined in X-linked 
adrenoleukodystrophy 
 Oxidative stress is a condition resulting from a redox 
imbalance that leads to an excess of ROS. Due to high 
instability, ROS react with and induce chemical changes in 
surrounding molecules. These changes are detrimental if 
the modified residues happen to be essential for the activ-
ity or turnover of the molecule (Wang et al. , 2012 ). Mac-
romolecules such as DNA, lipids and proteins, are highly 
vulnerable to ROS attack. Moreover, oxidative lesions can 
also transform lipid properties and induce mutations in 
mitochondrial and nuclear DNA, causing mitochondrial 
dysfunction and pathology (Pamplona and Barja , 2007 ). 
 In X-ALD, we have identified a common signature 
present in the spinal cord of mice and brains of cAMN and 
cALD patients. This reflects a metabolic – inflammatory 
interplay through IkB kinase and oxidative stress induced 
by excess VLCFAs (Schluter et al. , 2012 ). Indeed, using 
a combination of proteomic approaches and mass spec-
trometry, we discovered that the absence of ABCD1 causes 
oxidative lesions in five key enzymes of glycolysis and 
the tricarboxylic acid cycle: aldolase A, phosphoglycer-
ate kinase, pyruvate kinase, dihydrolipoamide dehydro-
genase and aconitase (Galino et al. , 2011 ). Metabolomic 
measurements of different substrates and products con-
firmed that the oxidation of these enzymes inhibits their 
catalytic activity, thus decreasing NADH and ATP levels. 
This, in turn, results in a syndrome of energetic deficiency 
(Galino et al. , 2011 ). However, antioxidants halted the oxi-
dative stress-induced metabolic alterations in an X-ALD 
mouse model, normalizing NADH, ATP, NADPH and GSH 
levels (Galino et al. , 2011 ). These data lend support to the 
idea that there is metabolic derangement in the spinal 
cords of  Abcd1 - mice prior to the development of neurolog-
ical symptoms. Based on the animal data, it is reasonable 
to propose that the energy failure produced by oxidative 
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stress may be a physiopathogenic factor, at least in adult 
forms of X-ALD. 
 Nonetheless, oxidative stress is not an exclusive event 
of X-ALD; common neurodegenerative diseases such as 
Alzheimer ’ s, Huntington ’ s and Parkinson ’ s also show 
redox imbalance, protein oxidation and energetic failure 
(Lin and Beal , 2006 ; Pratico , 2008 ; Stack et al. , 2008 ; 
Zhou et al. , 2008 ; Martinez et al. , 2010 ). 
 Many of the aforementioned alterations reveal the 
high susceptibility of the CNS to oxidative damage, prob-
ably related to the large amount of highly peroxidizable 
polyunsaturated fatty acids in membranes, the presence 
of catecholamines prone to oxidation, elevated oxygen 
consumption, and the relatively poor expression of enzy-
matic antioxidant defenses (Lin and Beal , 2006 ; Naudi 
et al. , 2011 ). Moreover, neurons are more dependent on 
mitochondria than on glycolysis for ATP production, 
which renders them particularly vulnerable to mitochon-
drial dysfunction (Thannickal and Fanburg , 2000 ). 
 Oxidative stress and mitochondrial 
dysfunction 
 Mitochondria orchestrate essential functions, including 
ROS, calcium homeostasis, and energy generation, as well 
as cell survival and death. For this reason, optimal func-
tioning of mitochondria is required to preserve cell and 
organism viability. Mitochondria are highly susceptible 
to oxidative damage because they are the main producers 
of ROS as a byproduct of the electron transport chain. In 
the majority of neurometabolic disorders, mitochondrial 
dysfunction is a central marker of disease progression. 
Indeed, the accumulation of damaged mitochondria cor-
relates with the development of the disease (Lin and Beal , 
2006 ; Du and Yan , 2010 ; Fernandez -Checa et al., 2010 ; 
Blackstone and Chang , 2011 ). 
 The mitochondrial permeability transition pore (mPTP) is 
a protein pore formed in the inner membrane of the mitochon-
dria under certain pathological conditions, allowing the flux 
of solutes of up to 1500 Da (Bernardi et al. , 2006 ; Halestrap , 
2009 ). This results in the dissipation of mitochondrial mem-
brane potential and damage to the mitochondrial respiratory 
chain, thereby reducing ATP production and exacerbating 
mitochondrial dysfunction. Moreover, there is osmotic swell-
ing that ruptures the outer mitochondrial membrane (Baines 
et al. , 2005 ; Bernardi et al. , 2006 ; Du and Yan , 2010 ). Overall, 
these phenomena irreversibly trigger cell death (Petronilli 
et al. , 1994 ; Baines et al. , 2005 ; Halestrap , 2005 ; Nakagawa 
et al. , 2005 ). 
 Although the role of mPTP in pathological conditions 
has been widely established, the nature and identity of the 
molecular components of the pore are still under discus-
sion, with CypD being the only component that appears 
to be essential (Baines et al. , 2005 ; Nakagawa et al. , 2005 ; 
Schinzel et al. , 2005 ). CypD is an 18 kDa peptidyl-prolyl-
 cis - trans -isomerase located in the mitochondrial matrix. 
In physiological conditions it plays an important role in 
protein folding due to its ability to catalyze the  cis - trans 
isomerization of peptidylprolyl bonds (Schonbrunner 
et al. , 1991 ). However, once certain pathological condi-
tions are established, CypD is translocated to the inner 
mitochondrial membrane to induce the opening of the 
mPTP (Connern and Halestrap , 1994 ). The genetic abro-
gation of CypD prevents mPTP formation under oxidative 
stress and/or calcium overload (Baines et al. , 2005 ), sup-
porting the essential role of CypD in mPTP formation. 
 The mitochondrial permeability 
transition pore in the physio-
pathogenesis of X-linked 
adrenoleukodystrophy 
 Many reports indicate that the formation of mPTP is a 
key factor in mitochondrial dysfunction and mitochon-
dria-driven cell death (Halestrap , 2005 ; Du and Yan , 
2010 ). These abnormalities are thus rescued by the addi-
tion of the CypD inhibitor CsA, or by the genetic blockade 
of CypD (Crompton et al. , 1988 ; Halestrap and Davidson , 
1990 ; Baines et al. , 2005 ). Indeed, the genetic abrogation 
of CypD prevents mitochondrial dysfunction in many 
age-related neurodegenerative disease models, such 
as Alzheimer ’ s disease (Du et al. , 2008 ), Parkinson ’ s 
disease (Gandhi et al. , 2009 ; Thomas et al. , 2011 ), amyo-
trophic lateral sclerosis (Karlsson et al. , 2004 ; Martin 
et al. , 2009 ; Martin , 2010 ) and multiple sclerosis (Forte 
et al. , 2007 ). 
 ROS and calcium are potent inducers of mPTP opening 
(Baines et al. , 2005 ; Bernardi et al. , 2006 ; Du and Yan , 
2010 ). ROS and calcium signaling are altered in X-ALD 
(Fourcade et al. , 2008 ; Hein et al. , 2008 ), therefore we 
sought to determine whether both factors were relevant to 
X-ALD pathology. We recently reported that CypD is signif-
icantly increased in X-ALD mouse model spinal cords, in 
fibroblasts from X-ALD patients, and in the affected zones 
of brains from AMN patients (Lopez -Erauskin et al., 2012 ). 
This is reminiscent of the increased CypD expression 
reported in brains from patients with Alzheimer ’ s disease 
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(Du et al. , 2008 ) and Huntington ’ s disease (Shirendeb 
et al. , 2011 ). 
 Interestingly, antioxidant treatment was able to reduce 
the high levels of CypD observed in fibroblasts from X-ALD 
patients and in spinal cords from X-ALD mice (Lopez -
Erauskin et al., 2012 ). Also, the induction of oxidative stress 
in control human fibroblasts in a glucose-free medium 
containing galactose, or with an excess of C26:0, causes an 
increase in CypD protein expression (Lopez -Erauskin et al., 
2012 ). All in all, the evidence indicates that CypD expression 
depends on the redox state. Moreover, not only the expres-
sion but also the activity of CypD may be regulated by oxi-
dative stress, since we detected oxidative modifications in 
CypD in X-ALD fibroblasts, which can be reversed by clas-
sical antioxidants both  in vivo and  in vitro (Lopez -Erauskin 
et al., 2012 ). In accordance with this, it has been suggested 
that CypD is a redox sensor (Linard et al. , 2009 ; Nguyen 
et al. , 2011 ). Linard and coworkers identified cysteine 203 
in CypD as being a redox-sensitive residue, and reported 
a reduction in oxidative stress-induced CypD peptidyl-
prolyl- cis-trans -isomerase activity, together with oxida-
tive stress-induced CypD protein conformational changes 
(Linard et al. , 2009 ). It was proposed that, once oxidative 
stress is triggered, the oxidation state of CypD induces con-
formational changes in its structure, promoting its translo-
cation to the inner mitochondrial membrane via the mPTP 
opening, which eventually contributes to the necrotic 
death process. 
 Along these lines, the finding that CsA, the CypD 
inhibitor, prevented the galactose-induced cell death of 
X-ALD fibroblasts (Lopez -Erauskin et al., 2012 ) confirms 
that CypD mediates the damage brought about by oxida-
tive stress in X-ALD. 
 Although the relevance of CypD in X-ALD will only be 
unequivocally confirmed by the genetic ablation of CypD, 
with all the evidence obtained thus far we may suggest that 
the oxidative stress-induced and CypD-dependent opening 
of mPTP is a central feature of X-ALD. We therefore propose 
that CypD is a key molecule in X-ALD physio pathology and 
is an important new target for therapeutic intervention. 
 Concluding remarks 
 X-linked adrenoleukodystrophy is caused 
by the oxidative stress-initiated interplay of 
mitochondrial collapse and energetic failure 
 Our working model is as follows (Figure  1 A). ROS, gener-
ated by C26:0 accumulation, induce energetic failure by 
oxidizing glycolytic and tricarboxylic acid cycle enzymes, 
which leads to a decrease in NADH and ATP content. The 
parallel decrease of GSH, the most important antioxidant 
defense of the cell, will contribute to the oxidative stress. 
The increased ROS content further worsens mitochondrial 
dysfunction by opening the mPTP, which in turn is exacer-
bated by the translocation of oxidized and overexpressed 
CypD to the inner mitochondrial membrane. That is, oxi-
dative stress causes cell death in X-ALD in association 
with severe mitochondrial dysfunction, leading to meta-
bolic failure. As a word of caution, it should be stressed 
that the above conclusions refer to skin fibroblasts. A 
precise dissection of the role played by mitochondria dys-
function compared to other sources of free radicals needs 
to be undertaken in the different neural cell types of the 
nervous system. 
 Cyclophilin D is a novel therapeutic target 
 The inhibition of CypD overexpression and activation pre-
vents mPTP opening, thereby preventing mitochondria 
swelling and changes in the membrane potential, and ini-
tiating the mitochondria-dependent cell death cascade. 
 X-linked adrenoleukodystrophy as a model 
of neurodegenerative and non-neurodegen-
erative diseases distinguished by alterations 
in redox homeostasis 
 Oxidative stress, mitochondrial dysfunction and energetic 
failure are common to a number of ailments irrespective of 
the initial cause (Galea et al. , 2012 ). It has been described 
how abnormally aggregated proteins act as molecular 
signals to induce CypD translocation to the inner mito-
chondrial membrane, resulting in mitochondrial dys-
function. Du and coworkers reported the existence of 
amyloid- β (A β )-CypD complexes in the mitochondria of 
cortical neurons in amyloid precursor protein-overex-
pressing mice, a model of Alzheimer ’ s disease. These 
complexes promote ROS generation and CypD recruit-
ment to the inner mitochondrial membrane, triggering the 
opening of the mPTP and subsequent cell death (Du et al. , 
2008 ). Considering the absence of protein aggregates in 
X-ALD, we propose that molecular signals involved in the 
CypD translocation to the inner mitochondrial membrane 
are triggered by oxidative stress-induced CypD expres-
sion and the direct oxidation of CypD protein, instead 
of amyloid beta, the molecular signal involved in CypD 
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 Figure 1   Working model for the molecular events underlying axonal degeneration and the action of antioxidants in the prevention of 
X-linked adrenoleukodystrophy. 
 (A) Mutations in the ABCD1 gene produce C26:0 accumulation and reactive oxygen species (ROS) generation as a consequence. This affects 
glycolysis and the tricarboxylic acid cycle through the oxidation of the enzymes involved, thereby decreasing their activity. Hence, reduced 
levels of NADH and ATP lead to energetic deficiency. High levels of ROS consume glutathione levels, which become depleted. Further, 
ROS oxidize mitochondrial cyclophilin D inducing its translocation to the inner mitochondrial membrane and triggering the mitochondrial 
permeability transition pore opening. This results in inner mitochondrial membrane depolarization, mitochondrial swelling and subsequent 
cell death. (B) Antioxidant treatment decreases ROS levels, thus abrogating protein oxidation and preventing the impairment of glycolysis 
and the tricarboxylic acid cycle as well as the mitochondrial permeability transition pore opening. Likewise, lowered ROS content allows for 
the recovery of reduced glutathione levels and contributes to the maintenance of redox homeostasis.  Δ Ψ m: Inner mitochondrial membrane 
potential; C: cytosol; I: intermembrane space; M: matrix. 
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translocation to the inner mitochondrial membrane in 
Alzheimer ’ s disease. 
 Antioxidants as a potential treatment 
against cyclophilin D-dependent diseases 
 As shown in Figure 1B, antioxidants acting against C26:0-
induced ROS prevent enzyme oxidation, thus normalizing 
ATP and NADH content. Moreover, normalized GSH levels 
help to maintain redox homeostasis, preventing CypD 
oxidation and the subsequent mPTP opening. In addition 
to reversing oxidative lesions in CypD, antioxidants may 
contribute to the repair of already initiated CypD-depend-
ent mitochondrial dysfunction. That is antioxidants could 
serve as mPTP opening inhibitors, which implies the 
rational use of these molecules for the treatment of CypD-
dependent diseases. 
 Received November 13, 2012; accepted March 2, 2013; previously 
published online March 14, 2013 
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